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Abstract
Background: Patients with large defects in the annulus fibrosus following lumbar discectomy have high rates of symptomatic
reherniation. The Barricaid annular closure device provides durable occlusion of the annular defect and has been shown to
significantly lower the risk of symptomatic reherniation in a large European randomized trial. However, the performance of the
Barricaid device in a United States (US) population has not been previously reported.
Design andmethods: This is a historically controlled post-market multicenter study to determine the safety and efficacy of the
Barricaid device when used in addition to primary lumbar discectomy in a US population. A total of 75 patients with large annular
defects will receive the Barricaid device following lumbar discectomy at up to 25 sites in the US and will return for clinical and imaging
follow-up at 4 weeks, 3 months, and 1 year. Trial oversight will be provided by a data safety monitoring board and imaging studies will
be read by an independent imaging core laboratory. Patients treated with the Barricaid device in a previous European randomized
trial with comparable eligibility criteria, surgical procedures, and outcome measures will serve as historical controls. Main outcomes
will include back pain severity, leg pain severity, Oswestry Disability Index, health utility on the EuroQol-5 Dimension questionnaire,
complications, symptomatic reherniation, and reoperation. Propensity score adjustment using inverse probability of treatment
weighting will be used to adjust for differences in baseline patient characteristics between the US trial participants and European
historical controls.
Ethics and dissemination: This study was approved by a central institutional review board. The study results of this trial will be
widely disseminated at conference proceedings and published in peer-reviewed journals. The outcomes of this study will have
important clinical and economic implications for all stakeholders involved in treating patients with lumbar discectomy in the US.
Study registration: ClinicalTrials.gov (https://clinicaltrials.gov): NCT03986580.
Level of evidence: 3.
Abbreviations: ASD = average standardized difference, EQ-5D = EuroQoL-5 Dimension, EU = European, IPTW = inverse
probability of treatment weighting, ODI = Oswestry Disability Index, US = United States.
Keywords: annular closure device, Barricaid, lumbar discectomy, lumbar herniation, sciatica
1. Introduction
Lumbar disc herniation is a localized displacement of disc material
beyond the normalmargins of the intervertebral disc space[1] and is
the primary cause of sciatica,which affects between 1%and 5%of
the adult population each year.[2] First-line treatments for sciatica
are nonsurgical and may consist of physical therapy, pharmaco-
logic therapy, and/or epidural steroid injection. Regardless of
whether conservative treatment is undertaken, acute sciatica
symptoms eventually subside in most patients.[3,4] In patients
whose symptoms are resistant to conservative treatments, lumbar
discectomy may be considered. Surgery typically results in faster
symptom relief than continued conservative care[5] and this clinical
advantage persists over longer term follow-up.[1] Consequently,
lumbar discectomy has emerged as one of the most commonly
performed spinal surgeries.[6]
Among patients undergoing lumbar discectomy, recurrent disc
herniation occurs in 7% to 18% of patients within 2 years.[7–10]
Symptomatic reherniation requires reoperation in nearly 80% of
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cases.[11] Patients at highest risk for reherniation are those with
an annular defect of at least 6mm width at completion of the
lumbar discectomy procedure.[12] This high-risk patient popula-
tion is easily identifiable by measuring the annular defect width
with a Penfield probe or specialized measurement tools.
Historically, there has been a considerable unmet therapeutic
need in this high-risk patient population. Over the last several
decades, multiple attempts at the development of techniques and
technologies to repair annular defects have been met with limited
success.[13]
A bone-anchored device intended to occlude large annular
defects after lumbar discectomy (Barricaid, Intrinsic Therapeu-
tics, Woburn, MA) received Food and Drug Administration
approval in 2019 based, in part, on 2-year safety and efficacy
results from a 554-patient randomized trial conducted in
Europe.[14] Due to potential regional differences in patient
characteristics or surgical practices, it is important to confirm the
generalizability of these results to patients in the United States
(US). The purpose of this historically controlled post-market
confirmatory study is to report the safety and efficacy of the
Barricaid annular closure device when used in addition to a
primary lumbar discectomy procedure in a US patient popula-
tion.
2. Design and methods
The protocol for this study was developed in accordance with the
SPIRIT 2013 guidance for protocols of clinical trials.[15]
2.1. Study design
This is a prospective, multicenter, single-arm, historically
controlled, confirmatory study that will be performed at up to
25 sites in the US. Patient recruitment is planned to begin in
February 2020. The total study duration is expected to be 1.5
years, with 6 months of patient recruitment and 1 year of follow-
up. Patient outcomes in this US trial of the Barricaid device (US
Barricaid) will be descriptively compared with those from the
Barricaid arm of a European randomized controlled trial
consisting of 276 patients (EU Barricaid Controls).[14] Propensity
score methods will be used to adjust for differences in baseline
patient characteristics between the US Barricaid patients and EU
Barricaid Controls. The trial was prospectively registered at
ClinicalTrials.gov (NCT03986580) before first patient enroll-
ment. Trial oversight will be provided by a data safety monitoring
board and data will be routinely monitored for accuracy.
2.2. Participants and eligibility criteria
Participants will undergo preoperative axial and sagittal
magnetic resonance imaging (MRI) of the lumbar spine, low-
dose multiplanar computed tomography of the target lumbar
level, and 4-view x-rays (standing flexion-extension, lateral,
anteroposterior). Key eligibility criteria are lumbar disc hernia-
tion at L4–L5 or L5–S1, leg pain severity at least 40mm on a
visual analogue scale of 100mm length, a score of at least 40 on
the Oswestry Disability Index (ODI)[16] despite at least 6 weeks of
nonsurgical management, and a positive straight leg raise sign on
physical examination. Key exclusion criteria are previous spinal
surgery at the herniated level, spondylolisthesis with at least 25%
slip at the index level, and lumbar osteoporosis. Patients who
meet all preoperative eligibility criteria will undergo limited
lumbar discectomy during which the final eligibility criterion
regarding annular defect size will be evaluated. A complete list of
study eligibility criteria is provided in Table 1.
2.3. Surgical procedure
Patients will be treated with limited lumbar microdiscectomy
using an interlaminar transflaval approach as described by
Spengler.[17] At completion of the limited discectomy procedure,
patients will then be assessed for the final eligibility criterion by
measuring the size of the annular defect. Patients with a large
annular defect, defined as 4 to 6mm tall and 6 to 10mm wide,
will be enrolled in the trial and treated with the Barricaid device.
Patients with annular defect sizes outside of the eligible range will
be excluded from further trial participation.
The Barricaid device is a permanent implant that has 2 major
subcomponents: a flexible woven polymer fabric component
intended to close the annular defect, and a bone anchor to secure
the device to an adjacent vertebral body (Fig. 1). The occlusion
component consists of a flexible polymer that is designed to
prevent reherniation by physically blocking the annulus at the
post-surgery defect to maintain hydrostatic pressure inside the
nucleus pulposus,[18] and containing a platinum-iridium radi-
opaque marker to permit radiographic visualization. The anchor
component is a saw-toothed titanium alloy that is secured into
either the caudal-adjacent or cranial-adjacent vertebral body to
resist migration.
After confirmation of a large annular defect, an alignment trial
will be performed under fluoroscopic control to establish the
correct position and angle of the Barricaid device. Next, the
device will be implanted under fluoroscopic guidance by
impacting the anchor into the vertebral body while the occlusion
component simultaneously enters the annular defect to prevent
expulsion of disc material into the extradiscal space. After
fluoroscopic confirmation of correct device placement, the
surgical site will be inspected and standard wound closure will
be performed.
2.4. Outcomes
Follow-up visits will occur at 4 weeks, 3 months, and 1 year
posttreatment. Magnetic resonance imaging with axial and
sagittal images of the lumbar spine, low-dose multiplanar
computed tomography of the target level only, and x-rays will
be performed during follow-up. Back pain severity, leg pain
severity, ODI, EuroQol-5 Dimension (EQ-5D) questionnaire,
complications, symptomatic reherniation, and reoperation will
be assessed at each follow-up visit. A schedule of patient
assessments during the study is provided in Table 2.
Back and leg pain severity will be separately assessed on a 100
mm visual analogue scale. Back disability will be evaluated with
the ODI using a 0 to 100 scale where higher scores represent
greater disability. Health utility will be evaluated with the EQ-5D
questionnaire.[19] This patient-reported questionnaire consists of
5 domains (mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression), each of which can take 1 of 3 responses.
Possible responses include 3 levels of severity (no problems/some
or moderate problems/extreme problems) within each EQ-5D
dimension. The occurrence of adverse events will be evaluated at
each visit and adjudicated for seriousness and relation to the
procedure or device by an independent data safety monitoring
board. Symptomatic reherniation will be defined as: confirmed
Strenge et al. Medicine (2019) 98:35 Medicine
2
reherniation during a reoperation, imaging core lab confirmation
of reherniation based on MRI performed at an unscheduled visit
due to patient symptoms, or imaging core lab confirmation of
reherniation based on MRI performed at an scheduled visit in
patients with ODI ≥40 and positive leg raise sign, or with an
adverse event deemed related to reherniation, lumbar/leg pain, or
a neurological event (Fig. 2). Index-level reoperations will be
defined as any surgical procedure performed at the level of the
original herniation, regardless of side or reason, during follow-up.
An independent imaging core laboratory will read imaging to
assess device status and anatomical characteristics following the
procedure. Key imaging variables will include Modic changes,
Pfirrman grade, anterior and posterior ossification, spontaneous
fusion, disc degeneration, herniation recurrence, annular tears/
fissures, and device events such as device integrity, migration, and
subsidence.
The primary endpoint of the study is the incidence of
symptomatic reherniation through the 3-month follow-up visit.
Secondary endpoints of the study will include symptomatic
reherniation, reoperation, back pain severity, leg pain severity,
ODI, and adverse events at 3 months and 1-year follow-up.
2.5. Propensity score adjustment
We anticipate that patients enrolled in the US Barricaid trial may
differ from the EU Barricaid Controls with respect to certain
baseline characteristics. Therefore, we will prospectively collect




1. Age 18–75 years old and skeletally mature (male or female).
2. Subjects with posterior or posterolateral disc herniations at 1 level between L4 and S1 with radiographic confirmation of neural compression using MRI. (Note:
Intraoperatively, only patients with an annular defect [post discectomy] between 4 and 6mm tall and 6 and 10mm wide shall qualify.
3. At least 6 weeks of failed, conservative treatment prior to surgery, including physical therapy, use of anti-inflammatory medications at maximum specified dosage and/or
administration of epidural/facet injections.
4. Minimum posterior disc height of 5mm at the index level.
5. Radiculopathy (with or without back pain) with a positive straight leg raise (0–60°).
6. Oswestry questionnaire score of at least 40/100 at baseline.
7. VAS leg pain (one or both legs) of at least 40/100 at baseline.
8. Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements.
Exclusion criteria
1. Spondylolisthesis grade II or higher (25% slip or greater).
2. Subject requires spinal surgery other than a discectomy (with or without laminotomy) to treat leg/back pain (scar tissue and osteophyte removal is allowed).
3. Subject has back or non-radicular leg pain of unknown etiology.
4. Prior surgery at the index lumbar vertebral level.
5. Subject requiring a spine DEXA (i.e., patients with SCORE of ≥6) with a T score <–2.0 at the index level. For patients with a herniation at L5/S1, the average T score of
L1–L4 shall be used.
6. Subject has clinically compromised vertebral bodies in the lumbosacral region due to any traumatic, neoplastic, metabolic, or infectious pathology.
7. Subject has sustained pathologic fractures of the vertebra or multiple fractures of the vertebra or hip.
8. Subject has scoliosis of >10° (both angular and rotational).
9. Any metabolic bone disease.
10. Subject has an active infection either systemic or local.
11. Subject has cauda equina syndrome or neurogenic bowel/bladder dysfunction.
12. Subject has severe arterial insufficiency of the legs or other peripheral vascular disease. (Screening on physical examination for patients with diminution or absence of
dorsalis pedis or posterior tibialis pulses. If diminished or absent by palpation, then an arterial ultrasound is required with vascular plethysmography. If the absolute arterial
pressure is below 50mm of Hg at the calf or ankle level, then the patient is to be excluded.)
13. Subject has significant peripheral neuropathy, patient defined as a patient with Type I or Type II diabetes or similar systemic metabolic condition causing decreased
sensation in a stocking-like or non-radicular and non-dermatomal distribution in the lower extremities.
14. Subject has insulin-dependent diabetes mellitus.
15. Subject is morbidly obese (defined as a body mass index >40, or weighs >100 lbs over ideal body weight).
16. Subject has been diagnosed with active hepatitis, AIDS, or HIV.
17. Subject has been diagnosed with rheumatoid arthritis or other autoimmune disease.
18. Subject has a known allergy to titanium, polyethylene, or polyester materials.
19. Any subject that cannot have a baseline MRI taken.
20. Subject is pregnant or interested in becoming pregnant in the next 2 years.
21. Subject has active tuberculosis or has had tuberculosis in the past 3 years.
22. Subject has a history of active malignancy: a patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with
curative intent and there have been no signs or symptoms of the malignancy for at least 2 years.
23. Subject is immunologically suppressed, received steroids >1 month over the past year.
24. Currently taking anticoagulants, other than aspirin, unless the patient can be taken off the anticoagulant for surgery.
25. Subject has a current chemical/alcohol dependency or significant psychosocial disturbance.
26. Subject has a life expectancy of <3 years.
27. Subject is currently involved in active spinal litigation.
28. Subject is currently involved in another investigational study.
29. Subject is incarcerated.
30. Any contraindication for MRI (e.g., claustrophobia, contrast allergy).
MRI=magnetic resonance imaging.
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mass index, smoking history, level of herniation, average disc
height, herniation type, back pain severity, leg pain severity, and
ODI.Wewill also obtain patient-level data from the EU Barricaid
Controls for these variables from the study sponsor. We will then
calculate propensity scores using binomial logistic regression to
estimate the probability that patients would be enrolled in the US
Barricaid trial. Propensity score adjustment using inverse
probability of treatment weighting (IPTW) will be used to
control for potential baseline covariate imbalances between study
groups, thereby providing unbiased estimates of average
treatment effects. Compared with other methods of propensity
score adjustment such as stratification, matching, or covariate
adjustment, IPTW is preferable for the analysis of differences in
proportions,[20] which coincides with the planned primary
endpoint analysis of this trial. We will verify the performance
of the propensity score model by comparing the distribution of
covariates between study groups before and after propensity
score adjustment using the absolute average standardized
difference (ASD) statistic. The ASD will be calculated as the
difference in means or proportions between study groups divided
by the pooled standard deviation. A negligible difference between
treatment groups will be defined as an ASD of <0.1.[21]
2.6. Statistical analysis
Using aClopper-Pearson exact test, a sample size of 75 patients (70
evaluable at 3months) produces a 2-sided95%confidence interval
ranging from 0.4% to 10.2%when the symptomatic reherniation
rate is 3.0%. The primary endpoint will be calculated as the
number of patients who experience symptomatic reherniation
through the end of the 3-month follow-up visit (postoperative day
105) divided by the sum of patients who return for the 3-month
follow-up visit and all patients with confirmed symptomatic
reherniation who fail to return for this visit. The propensity score-
adjusted primary endpoint resultswill be descriptively reported for
patients treated with the Barricaid device in each study, with no
formal hypothesis testing. The difference in propensity score-
adjusted 3-month reherniation risk between the US Barricaid trial
participants and the EU Barricaid Controls will be reported as an
absolute risk difference and 95% confidence interval.
Primary study results will be derived from propensity score-
adjusted comparisons. Group comparisons without propensity-
score adjustment will be performed as a sensitivity analysis.
Baseline characteristics will be summarized with standard
descriptive statistics. Categorical variables will be described with
percents and counts. Continuous variables will be described with
means and standard deviations, or medians and ranges.
Longitudinal changes in patient-reported outcomes will be
evaluated with a mixed model analysis of variance. Categorical
efficacy data will be evaluated as the number of patients with an
event divided by the number of patients with follow-up data plus
the number of patients with an event whomiss the follow-up visit.
Symptomatic reherniation and reoperation rates will be evaluated
in a sensitivity analysis using Kaplan–Meier time-to-event
methods. Missing data imputation will not be performed.
2.7. Ethics and dissemination
The protocol for this clinical trial was approved by Western
Institutional Review Board (Puyallup, WA) and all enrolled
Figure 1. The Barricaid annular closure device. The device is comprised of a
flexible polymer occlusion component that is attached to a titanium bone
anchor.
Table 2
Study assessments at each follow-up interval.
Assessment Preop Surgery 4 weeks 3 months 1 year
Informed consent ▪
Demographics/medical history ▪
Pain medication ▪ ▪ ▪ ▪ ▪
Clinical/neurologic exam ▪ ▪ ▪ ▪ ▪
Neutral lateral/anteroposterior x-ray ▪ ▪ ▪ ▪ ▪
Flexion-extension x-ray ▪ ▪
Computed tomography (index level) ▪ ▪
Magnetic resonance imaging ▪ ▪ ▪
Patient-reported outcomes
∗
▪ ▪ ▪ ▪
Limited lumbar discectomy ▪
Annular closure device implantation ▪
Adverse events† → → → →
∗
Includes back pain severity, leg pain severity, Oswestry Disability Index, and EQ-5D.
† Adverse events were assessed continuously throughout the study.
Strenge et al. Medicine (2019) 98:35 Medicine
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subjects will provide informed consent before study participa-
tion. The study results will be widely disseminated at conference
presentations and published in peer-reviewed journals.
3. Discussion
Annular healing following lumbar discectomy occurs slowly, if at
all, and ultimately yields biomechanically inferior fibrous tissue
with reduced capacity to accommodate tensile force.[22–24] This
makes reherniation of disc material likely to occur under lower
biomechanical stresses, especially in patients with large post-
surgical annular defects. Several strategies to repair, replace, or
regenerate the damaged annulus have been evaluated yet none
have resulted in a clinically proven strategy to generate
appropriate healing and prevent reherniation. It is likely that
prior attempts at annulus repair have failed because exterior
repairs are not matched to the demands of intradiscal tensile
forces.[25] Since the Barricaid device is anchored into an adjacent
vertebral body, this may provide for a more durable repair.
The primary goal of this prospective post-market study of the
Barricaid annular closure device is to determine whether clinical
outcomes with this device in the US are comparable to those
observed in a previous randomized trial with the same device in
Europe.[14] The design of this study and the conclusions to be
drawn will be strengthened by the fact that patient eligibility
criteria, surgical technique, device characteristics, and follow-up
methodology including imaging and outcome reporting are
comparable in the US Barricaid Trial and the EU Barricaid
Controls. Further, potential group differences in important
patient characteristics will be accounted for using propensity
score methods. Thus, this observational study was appropriately
designed to control for several important design factors that
might have otherwise introduced bias into the results.
The primary endpoint of this study will be evaluated at 3
months and patients will continue in follow-up for 1 year after
surgery. Although it could be argued that longer follow-up is
needed in this relatively young patient population, the 3-month
primary endpoint analysis is justified since early clinical outcomes
in this patient population are highly predictive of long-term
recurrence risk. Using 3-year data from the EU Barricaid
Controls, we developed a Cox proportional hazards model that
included 15 variables including age, sex, body mass index, index
level, smoking history, symptomatic reherniation by 3 months,
back pain at baseline, back pain at 3 months, 3-month change in
back pain, leg pain at baseline, leg pain at 3 months, 3-month
change in leg pain, ODI at baseline, ODI at 3 months, and 3-
month change in ODI. In multivariate analysis, symptomatic
reherniation by 3 months and back pain severity at 3 months
were independently associated with symptomatic reherniation
risk at 3 years. Patients who were free from reherniation and with
back pain scores under 13/100 at 3-month follow-up had a 3-year
reherniation risk of 6.1%. In contrast, patients with early
reherniation or 3-month back pain scores of 13/100 or higher had
a 3-year reherniation risk of 22.6%. Additionally, the 1-year
follow-up duration is clinically justified; among patients with a
symptomatic reherniation through 3 years following Barricaid
treatment, 60% were identified within the first year.[26] Lastly,
clinical outcomes during the first year after surgery are important
Figure 2. Algorithm to determine occurrence of symptomatic reherniation. AE=adverse event, HNP=herniated nucleus pulposus, MRI=magnetic resonance
imaging, ODI=Oswestry Disability Index, VAS=visual analogue scale.
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metrics utilized by healthcare payers for making coverage
decisions on new medical technologies. Another potential
criticism of this study is a sample size of only 75 patients. This
sample size was determined by calculating the minimum number
of patients that would provide sufficient precision around the
primary endpoint estimate. While formal noninferiority testing
with patients in the US Barricaid Trial and the EU Barricaid
Controls would have been preferable, such a study would be
impractical since a sample size of over 1000 patients would be
required to provide sufficient statistical power.
The importance of this trial primarily relates to describing the
clinical performance of the Barricaid device in a US population
with large post-discectomy annular defects, which has not been
previously reported. Recurrent symptomatic herniation is
associated with poor clinical outcomes and requires a technically
demanding, expensive reoperation in most cases.[11] With almost
half a million lumbar discectomies performed in the US per
year,[27] and approximately 100,000 to 150,000 of these patients
at high risk for recurrence based on annular defect size,[12] this
poses a widespread, clinically important problem not only for
affected individuals but also for physicians, hospitals, and
healthcare payers. Several studies have reported cost savings
following Barricaid device implantation. Parker et al[28] reported
that use of the Barricaid device resulted in a $2200 savings per
person compared with lumbar discectomy alone. Ament et al[29]
derived similar conclusions in which lumbar discectomy was
$2100 less expensive when the Barricaid device was utilized.
Should the rates of symptomatic recurrence in the current study
approximate those observed in the EU Barricaid Controls, this
would provide sufficient evidence that the Barricaid device is
effective in reherniation prevention not only in European
patients, but also in a US population of high-risk lumbar
discectomy patients. The results of this study will have important
clinical and economic implications for all stakeholders involved
in treating patients with lumbar discectomy in the US.
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